腸チフスVI多糖体ワクチンの世界市場レポート 2025年

腸チフスVI多糖体ワクチンの市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は18.5％で、133億6,000万米ドルに成長します。予測期間の成長は、予防接種プログラムの拡大、世界の保健政策の重視、疫学的サーベイランス、旅行医学における需要の高まり、環境および社会的要因に起因すると考えられます。予測期間における主な動向は、研究開発投資、規制支援、疫学調査、公衆衛生意識などです。

腸チフスの有病率の増加が、今後の腸チフスVI多糖体ワクチン市場の成長を牽引すると予測されます。腸チフスは、サルモネラ菌（Salmonella typhi）によって引き起こされる感染症で、生命を脅かす可能性があり、通常、汚染された飲食物を通じて感染します。腸チフスVI多糖体ワクチンは、腸チフス菌（Salmonella enterica serovar Typhi：S.Typhi）による腸チフスに対して、成人および2歳以上の小児に予防接種を行います。例えば、2024年8月に英国の政府機関であるUK Health Security Agencyが発表したデータによると、イングランド、ウェールズ、北アイルランドにおける腸チフスの検査室確定症例は2021年から2022年にかけて増加し、S. Typhiの症例数は108から313に、S. Paratyphi Aの症例数は31から135に、S. Paratyphi Bの症例数は13から18に増加しています。その結果、腸チフスの有病率の上昇が腸チフスVI多糖体ワクチン市場の成長を促進しています。

予防接種キャンペーンの拡大が、今後数年間の腸チフスVI多糖体ワクチン市場の成長を促進すると予想されます。予防接種キャンペーンは、1種類または複数のワクチンを大規模な集団に迅速に提供するための戦略であり、通常、国または準国家レベルで組織されます。こうしたキャンペーンは、特に腸チフスが公衆衛生上大きな問題となっている地域において、腸チフスVI多糖体ワクチンを効果的に配布・使用するために極めて重要です。例えば、2022年4月、ネパール政府は、官民の世界・ヘルス・パートナーシップであるワクチン同盟（Gavi）、スイスを拠点とする政府間組織である世界保健機関（WHO）、米国を拠点とする人道支援組織である国連国際児童緊急基金（UNICEF）の支援を受けて、腸チフス混合ワクチン（TCV）を同国の定期予防接種プログラムに組み込むための新たな予防接種キャンペーンを開始しました。2022年4月8日から5月1日までの3週間にわたるこのキャンペーンは、15ヵ月から15歳までのすべての子どもたちにワクチンを接種することで、腸チフスに対する予防を迅速に強化し、ワクチン導入の効果を最大限に高め、深刻化する抗菌薬耐性問題に対処することを目的としています。5万カ所以上の予防接種会場が、学校を含む国内の農村部と都市部の両方に設置されています。このように、予防接種キャンペーンの増加が腸チフスVI多糖体ワクチン市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の腸チフスVI多糖体ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の腸チフスVI多糖体ワクチン市場：成長率分析
• 世界の腸チフスVI多糖体ワクチン市場の実績：規模と成長, 2019-2024
• 世界の腸チフスVI多糖体ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の腸チフスVI多糖体ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腸チフスVI多糖体ワクチン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子供
• 成人
• 世界の腸チフスVI多糖体ワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 非経口
• 世界の腸チフスVI多糖体ワクチン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 政府機関
• 民間セクター
• その他の用途
• 世界の腸チフスVI多糖体ワクチン市場：子供のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児用製剤
• 年齢別投与
• 世界の腸チフスVI多糖体ワクチン市場：成人のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準成人向け製剤
• 高リスク集団向け製剤

第7章 地域別・国別分析

• 世界の腸チフスVI多糖体ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腸チフスVI多糖体ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腸チフスVI多糖体ワクチン市場：競合情勢
• 腸チフスVI多糖体ワクチン市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Emergent Biosolutions Inc.
• PT Bio Farma
• Bharat Biotech International Limited
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Bio-Med Pvt. Ltd.
• LG Chem
• SK Chemicals Co. Ltd.
• Crucell Switzerland AG
• Hualan Biological Engineering Inc.
• Indian Immunologicals Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腸チフスVI多糖体ワクチン市場2029：新たな機会を提供する国
• 腸チフスVI多糖体ワクチン市場2029：新たな機会を提供するセグメント
• 腸チフスVI多糖体ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The Typhoid Vi polysaccharide vaccine is recommended for active immunization in individuals aged two and older to prevent typhoid fever caused by Salmonella typhi.

The primary variants of this vaccine are tailored for pediatric and adult use. A child denotes an individual from birth to puberty or reaching full physical maturity. The vaccine can be administered orally or through parenteral routes and is accessible across governmental, private, and other institutional healthcare settings.

The typhoid Vi polysaccharide vaccine market research report is one of a series of new reports from The Business Research Company that provides typhoid Vi polysaccharide vaccine market statistics, including typhoid Vi polysaccharide vaccine industry global market size, regional shares, competitors with typhoid Vi polysaccharide vaccine market share, detailed typhoid Vi polysaccharide vaccine market segments, market trends and opportunities, and any further data you may need to thrive in typhoid Vi polysaccharide vaccine industry. This Typhoid Vi polysaccharide vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $5.78 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, vaccine efficacy and safety.

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $13.36 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to expanded immunization programs, global health policy focus, epidemiological surveillance, rising demand in travel medicine, environmental and social factors. Major trends in the forecast period include R&D investments, regulatory support, epidemiological studies, public health awareness.

The increasing prevalence of typhoid is anticipated to drive the growth of the typhoid VI polysaccharide vaccine market in the future. Typhoid is an infection caused by the bacteria Salmonella typhi, which can be life-threatening and is typically spread through contaminated food or drink. The Typhoid Vi polysaccharide vaccine is administered to immunize both adults and children aged two and older against typhoid fever caused by Salmonella enterica serovar Typhi (S. Typhi). For example, in August 2024, data published by the UK Health Security Agency, a government agency in the UK, revealed that laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland rose from 2021 to 2022, with cases of S. Typhi increasing from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the rising prevalence of typhoid is fueling the growth of the typhoid VI polysaccharide vaccine market.

The expansion of immunization campaigns is expected to drive the growth of the typhoid VI polysaccharide vaccine market in the coming years. Immunization campaigns are strategies designed to rapidly deliver one or more vaccines to large populations, typically organized at the national or sub-national level. These campaigns are crucial for the effective distribution and use of the typhoid VI polysaccharide vaccine, particularly in areas where typhoid fever presents a significant public health issue. For example, in April 2022, the Government of Nepal, with support from Gavi, the Vaccine Alliance-a public-private global health partnership-the World Health Organization (WHO), a Switzerland-based intergovernmental organization, and the United Nations International Children's Emergency Fund (UNICEF), a US-based humanitarian aid organization, launched a new vaccination campaign to incorporate the Typhoid Conjugate Vaccine (TCV) into the country's routine immunization program. This three-week campaign, running from April 8 to May 1, 2022, aims to vaccinate all children aged 15 months to 15 years to quickly enhance protection against typhoid, maximize the impact of the vaccine introduction, and address the growing issue of antimicrobial resistance. More than 50,000 vaccination sites have been set up across both rural and urban areas of the country, including schools. Thus, the increasing number of immunization campaigns is driving the growth of the typhoid VI polysaccharide vaccine market.

Increasing expenditure in the healthcare sector is anticipated to drive the growth of the typhoid VI polysaccharide vaccine market in the future. Healthcare expenditure encompasses the total costs associated with healthcare, including both public and private spending, as a percentage of GDP. Higher healthcare expenditure enables manufacturers of the typhoid VI polysaccharide vaccine to develop additional vaccines, thereby boosting demand in the market. For example, in September 2024, statistics released by Cross River Therapy, a US-based provider of ABA therapy services, indicated that the U.S. pharmaceutical industry generated $550 billion in revenue. Americans spent $576.9 billion on medications in 2021, with projected spending expected to rise to between $605 billion and $635 billion by 2025. Thus, the increasing expenditure in the healthcare sector is fueling the growth of the typhoid VI polysaccharide vaccine market.

Strategic partnerships are emerging as a significant trend in the typhoid VI polysaccharide vaccine market. Key players in this market are forming alliances to enhance their positions within the typhoid VI polysaccharide sector. For example, in July 2022, the International Vaccine Institute, an organization based in South Korea that focuses on infectious diseases of global health significance such as cholera, typhoid, shigella, and salmonella, collaborated with Moderna, a US-based biopharmaceutical firm. This partnership resulted in the development of the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Key companies in the typhoid VI polysaccharide vaccine market are prioritizing investments to maintain their competitive edge. Significant investments in the development and distribution of the typhoid VI polysaccharide vaccine highlight the critical importance of preventing and controlling typhoid fever. For instance, in August 2023, SK Bioscience, a South Korean biotech firm, and Vaxxas, an Australian biotechnology company specializing in a novel needle-free vaccination technology, secured AUD5.4 million (approximately $3.67 million) in funding from Wellcome, a UK-based charity. This funding aims to develop a typhoid conjugate vaccine that can be administered through a needle-free patch. This collaboration seeks to transform vaccine delivery by creating an innovative vaccine-delivery device that combines Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK Bioscience's proprietary typhoid vaccine.

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the typhoid vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The typhoid Vi polysaccharide vaccine market consists of sales of Vi capsular polysaccharide vaccine, and non-conjugated Vi polysaccharide vaccine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Typhoid Vi Polysaccharide Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on typhoid vi polysaccharide vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for typhoid vi polysaccharide vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The typhoid vi polysaccharide vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Child; Adult
• 2) By Route Of Administration: Oral; Parenteral
• 3) By Application: Government Institution; Private Sector; Other Applications
• Subsegments:
• 1) By Child: Pediatric Formulations; Age-Specific Dosages
• 2) By Adult: Standard Adult Formulations; High-Risk Population Formulations
• Companies Mentioned: Sanofi S.A.; GlaxoSmithKline PLC; Merck & Co. Inc.; Pfizer Inc.; Johnson & Johnson Private Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Typhoid Vi Polysaccharide Vaccine Market Characteristics

3. Typhoid Vi Polysaccharide Vaccine Market Trends And Strategies

4. Typhoid Vi Polysaccharide Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Typhoid Vi Polysaccharide Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Typhoid Vi Polysaccharide Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Typhoid Vi Polysaccharide Vaccine Market Growth Rate Analysis
• 5.4. Global Typhoid Vi Polysaccharide Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Typhoid Vi Polysaccharide Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Typhoid Vi Polysaccharide Vaccine Total Addressable Market (TAM)

6. Typhoid Vi Polysaccharide Vaccine Market Segmentation

• 6.1. Global Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Child
• Adult
• 6.2. Global Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.3. Global Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Government Institution
• Private Sector
• Other Applications
• 6.4. Global Typhoid Vi Polysaccharide Vaccine Market, Sub-Segmentation Of Child, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Formulations
• Age-Specific Dosages
• 6.5. Global Typhoid Vi Polysaccharide Vaccine Market, Sub-Segmentation Of Adult, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Adult Formulations
• High-Risk Population Formulations

7. Typhoid Vi Polysaccharide Vaccine Market Regional And Country Analysis

• 7.1. Global Typhoid Vi Polysaccharide Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Typhoid Vi Polysaccharide Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market

• 8.1. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Typhoid Vi Polysaccharide Vaccine Market

• 9.1. China Typhoid Vi Polysaccharide Vaccine Market Overview
• 9.2. China Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Typhoid Vi Polysaccharide Vaccine Market

• 10.1. India Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Typhoid Vi Polysaccharide Vaccine Market

• 11.1. Japan Typhoid Vi Polysaccharide Vaccine Market Overview
• 11.2. Japan Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Typhoid Vi Polysaccharide Vaccine Market

• 12.1. Australia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Typhoid Vi Polysaccharide Vaccine Market

• 13.1. Indonesia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Typhoid Vi Polysaccharide Vaccine Market

• 14.1. South Korea Typhoid Vi Polysaccharide Vaccine Market Overview
• 14.2. South Korea Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Typhoid Vi Polysaccharide Vaccine Market

• 15.1. Western Europe Typhoid Vi Polysaccharide Vaccine Market Overview
• 15.2. Western Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Typhoid Vi Polysaccharide Vaccine Market

• 16.1. UK Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Typhoid Vi Polysaccharide Vaccine Market

• 17.1. Germany Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Typhoid Vi Polysaccharide Vaccine Market

• 18.1. France Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Typhoid Vi Polysaccharide Vaccine Market

• 19.1. Italy Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Typhoid Vi Polysaccharide Vaccine Market

• 20.1. Spain Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market

• 21.1. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market Overview
• 21.2. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Typhoid Vi Polysaccharide Vaccine Market

• 22.1. Russia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Typhoid Vi Polysaccharide Vaccine Market

• 23.1. North America Typhoid Vi Polysaccharide Vaccine Market Overview
• 23.2. North America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Typhoid Vi Polysaccharide Vaccine Market

• 24.1. USA Typhoid Vi Polysaccharide Vaccine Market Overview
• 24.2. USA Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Typhoid Vi Polysaccharide Vaccine Market

• 25.1. Canada Typhoid Vi Polysaccharide Vaccine Market Overview
• 25.2. Canada Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Typhoid Vi Polysaccharide Vaccine Market

• 26.1. South America Typhoid Vi Polysaccharide Vaccine Market Overview
• 26.2. South America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Typhoid Vi Polysaccharide Vaccine Market

• 27.1. Brazil Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Typhoid Vi Polysaccharide Vaccine Market

• 28.1. Middle East Typhoid Vi Polysaccharide Vaccine Market Overview
• 28.2. Middle East Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Typhoid Vi Polysaccharide Vaccine Market

• 29.1. Africa Typhoid Vi Polysaccharide Vaccine Market Overview
• 29.2. Africa Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Typhoid Vi Polysaccharide Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Typhoid Vi Polysaccharide Vaccine Market Competitive Landscape
• 30.2. Typhoid Vi Polysaccharide Vaccine Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis

31. Typhoid Vi Polysaccharide Vaccine Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Mallinckrodt Pharmaceuticals
• 31.5. Emergent Biosolutions Inc.
• 31.6. PT Bio Farma
• 31.7. Bharat Biotech International Limited
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Novartis AG
• 31.10. Bio-Med Pvt. Ltd.
• 31.11. LG Chem
• 31.12. SK Chemicals Co. Ltd.
• 31.13. Crucell Switzerland AG
• 31.14. Hualan Biological Engineering Inc.
• 31.15. Indian Immunologicals Limited

32. Global Typhoid Vi Polysaccharide Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Typhoid Vi Polysaccharide Vaccine Market

34. Recent Developments In The Typhoid Vi Polysaccharide Vaccine Market

35. Typhoid Vi Polysaccharide Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Typhoid Vi Polysaccharide Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Typhoid Vi Polysaccharide Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Typhoid Vi Polysaccharide Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer